GE Healthcare expects supplies of its iohexol and iodixanol intraveneous contrast media products for computed tomography imaging to return to normal in the next few weeks. Customers can check this webpage weekly for an update on stock availability. A COVID-19 lockdown in China last year temporarily shut down the company’s production facility for iodinated contrast media, prompting global shortages of the two products.

Related News Articles

Headline
The Centers for Medicare & Medicaid Services May 31 released regulatory changes to the COVID-19 health care staff vaccination requirements and long-term…
#HealthCareInnovation Blog
In the fall of 2021, two years into the COVID-19 pandemic in the U.S., nearly 80% of adults said they had heard “at least one of eight different false…
Headline
The National Institute for Occupational Safety and Health this week revoked eight N95 filtering facepiece respirator approvals and four powered air-…
Headline
The Centers for Medicare and Medicaid Services released a FAQ regarding Consolidated Appropriations Act changes for states redetermining Medicaid enrollee…
Headline
Telehealth Access for America, an AHA-supported campaign to protect patient access to critical telehealth services, urged Congress to make permanent certain…
Headline
The Department of Health and Human Services May 11 amended its Public Readiness and Emergency Preparedness Act declaration for COVID-19 to extend…